Skip to main content
Top
Published in: Diabetologia 3/2019

01-03-2019 | Article

Type 2 diabetes mellitus, brain atrophy and cognitive decline in older people: a longitudinal study

Authors: Michele L. Callisaya, Richard Beare, Chris Moran, Thanh Phan, Wei Wang, Velandai K. Srikanth

Published in: Diabetologia | Issue 3/2019

Login to get access

Abstract

Aims/hypothesis

The aims of the study were to examine whether type 2 diabetes mellitus is associated with greater brain atrophy and cognitive decline, and whether brain atrophy mediates associations between type 2 diabetes and cognitive decline.

Methods

Participants without dementia aged 55–90 years from the Cognition and Diabetes in Older Tasmanians (CDOT) study underwent brain MRI (ventricular and total brain volume) and neuropsychological measures (global function and seven cognitive domains) at three time points over 4.6 years. Mixed models were used to examine longitudinal associations of type 2 diabetes with cognitive and MRI measures, adjusting for covariates. A test of mediation was used to determine whether brain atrophy explained associations between type 2 diabetes and cognitive decline.

Results

A total of 705 participants (diabetes: n = 348, mean age 68.2 years [SD 7.0]; no diabetes: n = 357, mean age 72.5 years [SD 7.1]) were available at baseline. Adjusting for age, sex, education and vascular risk factors, there were significant diabetes × time interactions for verbal memory (β −0.06; 95% CI −0.09, −0.02) and verbal fluency (β −0.03; 95% CI −0.06, −0.00). Although people with diabetes had lower brain (β −14.273; 95% CI −21.197, −6.580) and greater ventricular (β 2.672; 95% CI 0.152, 5.193) volumes at baseline, there were no significant diabetes × time interactions (p > 0.05) or evidence of mediation of the diabetes–cognition relationship by brain atrophy.

Conclusions/interpretation

In older community-dwelling people, type 2 diabetes is associated with decline in verbal memory and fluency over ~5 years. The effect of diabetes on brain atrophy may begin earlier (midlife).
Appendix
Available only for authorised users
Literature
1.
go back to reference Alzheimer’s Disease International (2014) World Alzheimer report. Alzheimer’s Disease International, London Alzheimer’s Disease International (2014) World Alzheimer report. Alzheimer’s Disease International, London
21.
go back to reference Lezak M (1995) Neuropsychological assessment. Oxford University Press, New York Lezak M (1995) Neuropsychological assessment. Oxford University Press, New York
22.
go back to reference Spreen O, Strauss E (1998) A compendium of neuropsychological tests. Administration, norms, and commentary. Oxford University Press, New York Spreen O, Strauss E (1998) A compendium of neuropsychological tests. Administration, norms, and commentary. Oxford University Press, New York
23.
go back to reference Weschler D (1997) Weschler Adult Intelligence Scale. Psychological Corporation, New York Weschler D (1997) Weschler Adult Intelligence Scale. Psychological Corporation, New York
27.
go back to reference Enders CK (2010) Applied missing data analysis. Guilford Press, New York Enders CK (2010) Applied missing data analysis. Guilford Press, New York
Metadata
Title
Type 2 diabetes mellitus, brain atrophy and cognitive decline in older people: a longitudinal study
Authors
Michele L. Callisaya
Richard Beare
Chris Moran
Thanh Phan
Wei Wang
Velandai K. Srikanth
Publication date
01-03-2019
Publisher
Springer Berlin Heidelberg
Published in
Diabetologia / Issue 3/2019
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-018-4778-9

Other articles of this Issue 3/2019

Diabetologia 3/2019 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.